Cardiac Changes After Effective Dose Carbetocin for Elective Caesarian Section
Opening soon Phase 4 NCT06946589
Run by Jordan Leitch · for 18 and older · Women
What this study is about
The goal of this project is to examine the cardiac symptoms and physiologic changes after administration of a reduced dose of carbetocin in participants undergoing elective cesarian section. * Does reduced dose carbetocin (50mcg) have fewer cardiac side effects than usual dose carbetocin (100mcg) when comparing patient reported symptoms, ECG changes and troponin increases? * Is there a relationship between patient reported cardiac symptoms after carbetocin administration and subjective measures of cardiac ischemia (ECG changes and troponin increases? Researchers will compare 50mcg of carbetocin to the control group of 100mcg of carbetocin in patients undergoing elective cesarian section. Participants will: * Be given 50mcg or 100mcg of carbetocin during cesarian section * Asked to report cardiac symptoms * Be assessed for ECG changes and blood loss using standard of practice monitoring * Have a troponin I blood test completed after delivery
Who can join (things the study team will check)
✅ You may be able to join if…
- Undergoing elective cesarian section
- Primary and repeat cesarian section
🚫 You may not be able to join if…
- Prior and current cardiovascular co-morbidities including pre-eclampsia
- BMI greater than 50
- Pre-existing bleeding disorders
- Allergy to carbetocin
- Age under 18
Where this trial is running
- Kingston Health Sciences Centre, Kingston, Ontario, Canada
Who to contact
Jordan Leitch, MD · 613-549-6666 · jordan.leitch@kingstonhsc.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06946589.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.